Why did Revvity (RVTY) stock move recently?

On 9/15/2026, Revvity moved +5.6% — Revvity rose after management highlighted growth in its diagnostics business at a healthcare investor conference. The company also recently agreed to acquire France-based Human Cell Design, which supplies human cell models used in metabolic disease drug discovery. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Revvity (RVTY) overvalued or fairly valued?

MarketChacha shows Revvity's valuation in context — a trailing P/E of about 92.9, a forward P/E of about 26.4, a price-to-book of about 2.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Revvity's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.08×) from reported figures — education, not a rating.

What is Revvity's revenue?

Revvity reported revenue of $2.9B for FY2025, with net profit of $241.2M, per official filings.

What is the share price of Revvity (RVTY)?

Revvity last traded at $156.99 (+4.0% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Revvity

RVTY · NYSE · Healthcare · United States

Snapshot

TickerRVTY

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees11,000

HeadquartersWaltham, United States

Websitewww.revvity.com

Filings tracked13

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

778 institutional holders

Ownership breakdown from public market data.

Top holders

T. Rowe Price Investment Management, Inc.16.37%
Jupiter Topco LLC7.74%
Edgepoint Investment Group Inc.7.66%
Blackrock Inc.6.86%
Vanguard Capital Management LLC6.54%
Price (T.Rowe) Associates Inc4.96%
Vanguard Portfolio Management LLC4.28%
State Street Corporation3.89%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 16.8 points over the period — profitability is trending down.

Cash conversion1.08×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend25.2% → 8.4%

Margin has compressed by about 16.8 points over the period — profitability is trending down.

Return on equity3.3%

Latest ROE of 3.3% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 2% · PAT -41%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $759.5M · EPS 1.61

Est. earnings growth -5.1%

Next fiscal year

Rev $3.0B · EPS 5.89

Est. earnings growth +10.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.9B

Net margin

8.4%

ROE

3.3%

Revenue CAGR (2y)

+1.9%

Profit CAGR (2y)

-41.0%

EPS (FY2025)

2.07

Net profit (FY2025)

$241.2M

Ask MarketChacha about RVTY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 15, 2026
Revvity rose after management highlighted growth in its diagnostics business at a healthcare investor conference. The company also recently agreed to acquire France-based Human Cell Design, which supplies human cell models used in metabolic disease drug discovery.
source 1 ↗· confidence: medium

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.9B	$241.2M	2.07	8.4%	3.3%
FY2024	$2.8B	$270.4M	2.20	9.8%	3.5%
FY2023	$2.8B	$693.1M	5.55	25.2%	9.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q3	$729.7M	$51.8M	0.47	7.1%
2026Q2	$711.1M	$40.7M	0.36	5.7%
2025Q3	$698.9M	$46.7M	0.40	6.7%
2025Q2	$720.3M	$53.9M	0.46	7.5%
2025Q1	$664.8M	$42.2M	0.35	6.4%
2024Q3	$684.0M	$94.4M	0.77	13.8%
2024Q2	$691.7M	$55.4M	0.45	8.0%
2024Q1	$649.9M	$26.0M	0.21	4.0%
2023Q4	$670.7M	$9.5M	0.08	1.4%
2023Q3	$709.1M	$35.6M	0.28	5.0%
2023Q2	$674.9M	$569.5M*	4.50	—
2023Q1	$741.2M	$127.7M	1.01	17.2%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/11/2026
8-K — Results of operations, Other events, Exhibits
SEC8/4/2026material
10-Q filing
SEC5/12/2026
8-K — Results of operations, Other events, Exhibits
SEC5/5/2026material
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/1/2026material
10-K filing
SEC2/24/2026
8-K — Results of operations, Exhibits
SEC2/2/2026material
8-K — Results of operations, Reg FD disclosure
SEC1/13/2026material

2025

10-Q filing
SEC11/4/2025
8-K — Results of operations, Exhibits
SEC10/27/2025material
8-K — Executive/director change
SEC10/24/2025material
10-Q filing
SEC8/5/2025
8-K — Results of operations, Exhibits
SEC7/28/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.